Page 43 - MemoriaCIBER2019-ENG

CIBERCV 43
Presentation by the Scientific Director
Francisco Fernández-Avilés
The third year in the development of the area of CIBERCV has been unquestionably satisfactory, both due to the achievements attained and to the great involvement of all the groups, which have managed to overcome a consid- erable amount of difficulties.
In 2019 we passed the second evaluation of the External Scientific Advisory Committee. In addition, we have managed to undertake a large part of the actions recommended by the Committee in its 2018 evaluation, striving for inter- nationalisation and excellence, with actions to identify, attract and retain young talent, promoting and rewarding multidisciplinarity and enhancing the management of data and registers in population cohorts.
The Management Committee is well aware that all the groups are making great efforts to ensure progress in these fields. In this third year, our CIBER has managed to participate in an IMI2 H2020 project with the participation of 4 CI- BERCV groups for the early identification of myocardial damage in patients with Type 2 Diabetes Mellitus. In addition, the CIBERCLAP platform has been launched with the aim of establishing the first multicenter large animal research network to test different cardio-protection strategies, and the CORDELIA consortium, a compiler of 26 population cohorts (> 120,000 subjects) with up to 15 years of follow-up to identify clinical predictors and molecular events of cardiovascular events has been closed.
Furthermore, in 2019, the main actions of the CIBERCV have continued to be implemented, such as the competitive grants through intramural projects and through actions to identify and promote talent through the Jordi Soler-Soler grants. Among the important scientific achievements, several multicentre studies led by researchers from the CIBER stand out. Another important milestone of this 2019 has been the implementation of the agreement with the Spanish Medicines Agency for the creation of a National Registry of Ventricular Assist Devices and that will allow progress in the comprehensive management of data provided by the national health system.
Despite multiple difficulties, we are optimistic and are aware that science managers are also committed to over- coming the struggles we face. The Consortium that welcomes us is an unrivaled venue of excellence that ensures a stable budget. All this is allowing us to place Spanish cooperative cardiovascular research at the highest national and international level of competitiveness. Thanks to you all.